Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyCigna Ekterly (sebetralstat) Coverage Update | Ope…
    Ask Trek AI about this page
    CurrentCignaPolicy IP0756

    Hereditary Angioedema - Ekterly

    Customize your policy alerts

    Sign up for Cigna Policy IP0756 alerts

    Get alerted when Policy IP0756 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage criteria for Ekterly (sebetralstat tablets) for treatment of acute hereditary angioedema (HAE) attacks in members of Cigna-administered health plans.

    Policy Summary
    PayerCigna
    PolicyHereditary Angioedema - Ekterly
    Policy CodePolicy IP0756
    Change TypeRoutine review — no material changes
    Effective DateAug 15, 2026
    Last ReviewAug 15, 2026
    Next Review DateAug 15, 2026
    Key ActionObtain prior authorization with required documentation and ensure prescriber is or consults an allergist/immunologist or HAE specialist.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥12Minimum age for therapy
    1 yearApproval duration
    Not coveredProphylaxis use
    Prior authAuthorization
    Specialist

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Prescriber requirement

    Coverage Criteria for Ekterly (sebetralstat)

    FDA-Approved Indication - Acute HAE attacks

    Ekterly is considered medically necessary when the following are met:

    FDA-Approved Indication: Approve for 1 year if the patient meets ONE of the following (A or B)
    A) Initial therapy: Patient is ≥ 12 years of age; AND patient has HAE type I or type II as confirmed by: (a) low functional C1-INH protein (<50% of normal) at baseline [documentation required]; AND (b) lower than normal serum C4 at baseline [documentation required]; AND medication is prescribed by or in consultation with an allergist/immunologist or physician who specializes in HAE or related disorders; AND preferred product criteria is met.

    HAE with normal C1-INH (HAE type III) does NOT satisfy this requirement.

    B) Patient who has treated previous HAE attacks with Ekterly: Patient has a diagnosis of HAE type I or type II [documentation required]; AND prescriber documents a favorable clinical response to Ekterly (examples include decreased duration of attacks, quick onset of symptom relief, complete resolution of symptoms, or decreased frequency/severity); AND medication is prescribed by or in consultation with an allergist/immunologist or physician who specializes in HAE or related disorders.

    If the patient is currently receiving the requested therapy but has not previously received approval through the Coverage Review Department, review under Initial Therapy criteria.

    Plan-level product criteria

    For certain plans, product-specific criteria apply (patient must meet one of the following):

    Plan criteria list: 1) Patient is ≥ 12 and < 18 years of age; OR 2) Patient has previously treated an acute HAE attack with Ekterly; OR 3) Patient has tried generic icatibant (for Individual/Family plans: generic icatibant or Sajazir).

    A previous trial of any icatibant product counts toward this requirement.

    Ekterly (sebetralstat) for any use other than the specified acute HAE treatment indication is not medically necessary. The policy explicitly lists non-covered uses and states that Ekterly for other indications outside the FDA-approved acute hereditary angioedema (HAE) attacks treatment is considered not medically necessary.

    Use of Ekterly for prophylaxis of HAE attacks is considered not medically necessary. The policy notes that data are not available and Ekterly is not indicated for HAE prophylaxis, and requests for this use will not be covered.

    Provider Actions, Authorization, and Documentation

    Prior Authorization

    Prior Authorization required; 1‑year approvals; specialist prescriber

    Prior authorization is required for benefit coverage of Ekterly. All approvals are provided for up to 1 year when coverage criteria are met. Ekterly must be prescribed by or in consultation with an allergist/immunologist or a physician who specializes in HAE or related disorders.

    Step Therapy

    Plan-level product criteria — Employer & Individual/Family

    For Employer and Individual/Family plans, coverage requires the patient to meet one of the plan-specific options: age ≥12 and <18 years, prior treatment of an acute HAE attack with Ekterly, or trial of generic icatibant (Individual/Family plans also accept Sajazir).

    • Employer plans: trial of generic icatibant satisfies requirement.
    • Individual/Family plans: trial of generic icatibant or Sajazir satisfies requirement.

    Background and Drug Information

    Ekterly (sebetralstat) is an oral plasma kallikrein inhibitor indicated for treatment of acute hereditary angioedema (HAE) attacks in patients meeting the FDA-approved criteria. Clinical guidelines recommend on-demand therapies for acute HAE attacks and include oral plasma kallikrein inhibitors among first-line options. Diagnostic confirmation for coverage requires HAE due to C1‑INH deficiency (HAE type I or II) with appropriate laboratory documentation; Ekterly is not indicated for prophylactic use and such use is not covered.

    Definitions

    inv-10: HAE type I/II — definition of hereditary angioedema due to C1-INH deficiency
    DefinitionHereditary angioedema (HAE) due to C1‑INH deficiency (HAE type I or II)
    Diagnostic criteriaLow functional C1‑INH protein (<50% of normal) at baseline AND low serum C4 at baseline (laboratory reference values; documentation required)
    Age requirementApplies to patients ≥ 12 years of age for Ekterly treatment
    Prescriber requirementMedication must be prescribed by or in consultation with an allergist/immunologist or physician who specializes in HAE
    Coverage implicationMeets the C1‑INH deficiency diagnostic criteria required for coverage under this policy (approve for up to 1 year when criteria met)
    inv-11: HAE with normal C1-INH (HAE type III) — definition and statement that it does not meet C1-INH deficiency criteria for coverage
    Policy Summary
    PayerCigna
    PolicyHereditary Angioedema - Ekterly
    Policy CodePolicy IP0756
    Change TypeRoutine review — no material changes
    Effective DateAug 15, 2026
    Last ReviewAug 15, 2026
    Next Review DateAug 15, 2026
    Key ActionObtain prior authorization with required documentation and ensure prescriber is or consults an allergist/immunologist or HAE specialist.
    SourceLink
    On This Page
    Coverage Criteria for Ekterly (sebetralstat)Provider Actions, Authorization, and DocumentationBackground and Drug InformationDefinitions
    Documentation Required

    Required documentation to support request

    Documentation must be provided as noted in the coverage criteria and may include chart notes, prescription claims/receipts, and other records; all documentation must include patient-identifying information.

    • For initial therapy: baseline lab results documenting low functional C1‑INH (<50% of normal) and low serum C4 as defined by lab reference values.
    • Diagnosis documentation confirming HAE type I or II.
    • For continuation: documentation of prior favorable clinical response to Ekterly when applicable.
    Denial Risk

    Denial triggers — no PA and non‑covered prophylaxis use

    Requests submitted without prior authorization will be denied; use of Ekterly for prophylaxis of HAE attacks is considered not medically necessary and will be denied.

    • A diagnosis of HAE with normal C1‑INH (HAE type III) does not meet criteria and will not satisfy coverage requirements.
    • If a patient is on therapy but lacks prior approval through the Coverage Review Department, initial therapy criteria must be met for approval.
    DefinitionHAE with normal C1‑INH (also known as HAE type III)
    Diagnostic statusDoes NOT satisfy the diagnostic criteria for C1‑INH deficiency required for coverage under this policy
    Evidence noteAn international consensus notes limited high‑level evidence for HAE‑nC1INH and multiple genes may be implicated; many patients lack an identified pathogenic variant
    Coverage implicationPatients with HAE‑nC1INH (HAE type III) are not eligible under the C1‑INH deficiency criteria for Ekterly coverage